These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17100706)

  • 1. Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation.
    Wente MN; Sauer P; Mehrabi A; Weitz J; Büchler MW; Schmidt J; Schemmer P
    Clin Transplant; 2006; 20 Suppl 17():80-4. PubMed ID: 17100706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified-release tacrolimus.
    Chisholm MA; Middleton MD
    Ann Pharmacother; 2006 Feb; 40(2):270-5. PubMed ID: 16449540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
    Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
    Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C; Lorenzin D; Rossetto A; Faraci MG; Nicolini D; Garelli P; Bresadola V; Toniutto P; Soardo G; Baroni GS; Adani GL; Risaliti A; Baccarani U
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR; Peeters PC; Sennesael JJ; Kianda MN; Vrijens B; Kristanto P; Dobbels F; Vanrenterghem Y; Kanaan N;
    Transplantation; 2013 Jan; 95(2):333-40. PubMed ID: 23263559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified release tacrolimus.
    First MR; Fitzsimmons WE
    Yonsei Med J; 2004 Dec; 45(6):1127-31. PubMed ID: 15627307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R; Lai C; Aceto P; Luciani M; Romagnoli J; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1020-3. PubMed ID: 21620041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus.
    Kurnatowska I; Krawczyk J; Oleksik T; Nowicki M
    Transplant Proc; 2011 Oct; 43(8):2954-6. PubMed ID: 21996199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan.
    Uemoto S; Abe R; Horike H; So M
    Transplant Proc; 2014 Apr; 46(3):749-53. PubMed ID: 24767340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients.
    Kausman JY; Patel B; Marks SD
    Pediatr Transplant; 2008 May; 12(3):329-35. PubMed ID: 18435608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.
    Grinyó JM; Petruzzelli S
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1567-79. PubMed ID: 25407098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies.
    van Hooff JP; Alloway RR; Trunečka P; Mourad M
    Clin Transplant; 2011; 25(1):E1-12. PubMed ID: 21158926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study.
    Doesch AO; Mueller S; Konstandin M; Celik S; Erbel C; Kristen A; Frankenstein L; Koch A; Dengler TJ; Ehlermann P; Zugck C; De Geest S; Katus HA
    Transplant Proc; 2010 Dec; 42(10):4238-42. PubMed ID: 21168673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase.
    Marzoa-Rivas R; Paniagua-Martín MJ; Barge-Caballero E; Pedrosa del Moral V; Barge-Caballero G; Grille-Cancela Z; Naya-Leira C; Fariñas-Garrido P; Blanco-Canosa P; Mosquera V; Castro-Beiras A; Crespo-Leiro MG
    Transplant Proc; 2010 Oct; 42(8):2994-6. PubMed ID: 20970591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis.
    Abecassis MM; Seifeldin R; Riordan ME
    Transplant Proc; 2008 Jun; 40(5):1443-5. PubMed ID: 18589126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.